Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • DecoPac Has Been Acquired by Sentinel Capital Partners

    William Blair served as financial advisor to DecoPac Inc., a portfolio company of Kohlberg & Company, in connection with its sale to Sentinel Capital Partners. The transaction closed in July 2026, and the terms were not disclosed.

    Read more

  • Inside the AI Economy: Competition, Compute, and the Next Phase of Enterprise Adoption

    William Blair's Arjun Bhatia and Jonathan Ho discuss the latest developments shaping the AI landscape, from intensifying model competition and pricing pressure to data center expansion, cybersecurity risks, and the pace of enterprise adoption.

    Listen to the podcast

  • Economics Weekly: The Dollar – Where to From Here?

    In this Economics Weekly, Richard de Chazal once again discusses the dollar—what is driving it in the near term and in which direction it is likely to head over the longer term.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures